Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ksq Therapeutics Inc. has 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct examiners and 4 distinct art units. This indicates that an examiner is handling multiple pending actions for the company. The concentration of 7 actions among 4 art units suggests a focused technological scope within the broader biotechnology field, where multiple applications are grouped within the same technical divisions.
TIWARI, VYOMA SHUBHAM is the busiest examiner for the portfolio, managing 2 pending office actions. This examiner's responsibility for 2 actions means that their specific examination style will have a larger impact on the portfolio than the other distinct examiners. For the practitioner, this creates an opportunity to apply successful arguments from a case to another handled by the same examiner. The overall distribution across 6 examiners for 7 actions still maintains a level of diversity in the prosecution process.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §112 only | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 2 | 32.1% | +47.4% |
| CHAO, ALLEN | 1 | 60.0% | +0.0% |
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16781732 | COMBINATION GENE TARGETS FOR IMPROVED IMMUNOTHERAPY | SHIN, DANA H | 28d overdue |
| 18547627 | METHODS FOR EXPANDING REGULATORY T CELLS | ALDARONDO, DASIA ALI | 21d |
| 18729657 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS FOR THE TREATMENT OF SOLID TUMORS | CHAO, ALLEN | — |
| 18689947 | LYMPHOCYTE POTENCY ASSAY | LANDSMAN, ROBERT S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17426059 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | SULLIVAN, STEPHANIE LAUREN | 31d overdue |
| 16781732 | COMBINATION GENE TARGETS FOR IMPROVED IMMUNOTHERAPY | SHIN, DANA H | 28d overdue |
| 18689947 | LYMPHOCYTE POTENCY ASSAY | LANDSMAN, ROBERT S | — |
| 17822183 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | TIWARI, VYOMA SHUBHAM | — |
| 17802080 | METHODS FOR ACTIVATION AND EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES | TIWARI, VYOMA SHUBHAM | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1634 | 2 |
| 1635 | 2 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729657 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS FOR THE TREATMENT OF SOLID TUMORS | CHAO, ALLEN | 1622 | §103§112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18689947 | LYMPHOCYTE POTENCY ASSAY | LANDSMAN, ROBERT S | 1647 | §102§103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18547627 | METHODS FOR EXPANDING REGULATORY T CELLS | ALDARONDO, DASIA ALI | 1647 | §102§103§112 | Final Rejection | 21d | Pending | Aug 23, 2023 |
| 17822183 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | TIWARI, VYOMA SHUBHAM | 1634 | §103 | Final Rejection | — | Pending | Aug 25, 2022 |
| 17802080 | METHODS FOR ACTIVATION AND EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES | TIWARI, VYOMA SHUBHAM | 1634 | §112 | Final Rejection | — | Pending | Aug 24, 2022 |
| 17426059 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Final Rejection | 31d overdue | Pending | Jul 27, 2021 |
| 16781732 | COMBINATION GENE TARGETS FOR IMPROVED IMMUNOTHERAPY | SHIN, DANA H | 1635 | §112Other | Final Rejection | 28d overdue | Pending | Feb 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKsq Therapeutics Inc. has 7 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Vyoma Shubham Tiwari has the most, with 2 of Ksq Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
